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Introduction {#sec1}
============

X-ray repair cross-complementing protein 1 (XRCC1) is a scaffold protein that coordinates the repair of DNA single-strand nicks and gaps (single strand breaks \[SSBs\]; [@bib7]). It constitutively associates with a DNA polymerase (Polβ) and a DNA ligase (Lig3α) to fill and ligate the broken strand ([@bib9], [@bib10], [@bib25], [@bib37]) and recruits the end-processing enzymes polynucleotide kinase-3′-phosphatase (PNKP) and aprataxin (APTX), which ensure the presence of 3′-hydroxyl and 5′-phosphate groups at gap margins ([@bib1], [@bib21], [@bib30]).

Recruitment of XRCC1 complexes to sites of DNA damage is strongly dependent on activation of the DNA-damage-responsive poly(ADP-ribose) polymerases PARP1 and PARP2 ([@bib16], [@bib18], [@bib36], [@bib43]). PARP-dependent recruitment of XRCC1 requires the central BRCT domain (BRCT1), which conserves components of a pocket similar to the phosphopeptide-binding BRCT domains in proteins such as TOPBP1 ([@bib42], [@bib51]). However, rather than interacting with phosphorylated proteins, the phosphate-binding pocket in XRCC1-BRCT1 has been shown to mediate interaction with the poly(ADP-ribose) (PAR) chains generated by PARP1 or PARP2 ([@bib6], [@bib29]).

Although an interaction with PAR plays a major role in recruiting XRCC1 to sites of DNA damage, several studies have suggested that XRCC1 is able to interact directly with DNA ([@bib32], [@bib39], [@bib40], [@bib47]) and that this plays a role in its DNA repair function ([@bib3], [@bib52]). Previous NMR studies implicated the N-terminal domain of XRCC1 in high-affinity interactions with gapped DNA molecules ([@bib33]), but subsequent work has cast doubt on this, and there is currently no coherent understanding of which part of XRCC1 is involved ([@bib31]). We show here that both PAR and DNA interactions are mediated by non-overlapping binding sites on the first of the two BRCT domains in XRCC1 (BRCT1). Targeted mutations in the DNA-binding site, which contains a common human polymorphism, impair XRCC1 interaction with DNA *in vitro* and markedly affect the kinetics of XRCC1 recruitment, its retention on damaged chromatin, and the efficiency of DNA single-strand break repair *in vivo*. These data resolve a critical unanswered question in the field.

Results {#sec2}
=======

XRCC1 Binds DNA through BRCT1 {#sec2.1}
-----------------------------

Previous studies had suggested that the N-terminal domain (NTD) of XRCC1, which is required for association of Polβ with XRCC1, possesses an inherent affinity for DNA with single-strand nicks and short gaps ([@bib33]). To discover whether other parts of XRCC1 might also be involved, we expressed and purified separate N-terminal (residues 1--223) and C-terminal (224--631) constructs of murine XRCC1 and examined their ability to interact with a 39-base-pair DNA duplex containing a single-strand nick, in an electrophoretic mobility shift assay (EMSA) (see [STAR Methods](#sec4){ref-type="sec"}). Contrary to the published model, we were unable to detect any significant interaction in EMSAs with the construct containing the NTD domain. By contrast, the C-terminal construct lacking the putative DNA binding NTD produced robust EMSA band shifts ([Figure 1](#fig1){ref-type="fig"}A). The marked difference in behavior of the two parts of XRCC1 suggests that its inherent DNA-binding ability resides in the C-terminal region, which incorporates the two BRCT domains, rather than in the Polβ-binding N-terminal domain.Figure 1XRCC1-BRCT1 Binds DNA(A) Electromobility shift assay (EMSA) shows that the ability to bind DNA resides in the C-terminal region of XRCC1 containing the two BRCT domains rather than the N-terminal region as previously suggested ([@bib33]).(B) Fluorescence polarization assay of XRCC1-BRCT1 binding to various fluorescein isothiocyanate (FITC)-labeled dsDNA oligonucleotides. No substantial differences in affinity were observed between intact, nicked, and gapped molecules, which all bound with sub-micromolar affinity. Oligonucleotide structures and *K*~d~ values for their binding to XRCC1-BRCT1 are shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A. Data represent the mean of four measurements comprised of two separate replicates with XRCC1-BRCT1 from two separate protein purifications. Error bars show ± 1 standard error of the mean (SEM).

As BRCT domains in other proteins have been implicated in binding to DNA ([@bib26] and references therein), and as PAR and DNA have many structural and chemical features in common, we considered the notion that BRCT1, which mediates the interaction of XRCC1 with PAR ([@bib6], [@bib29]), might also bind DNA. To address this, we expressed and purified the isolated BRCT1 domain of human XRCC1 and assessed its interaction with DNA using a fluorescence polarization assay (see [STAR Methods](#sec4){ref-type="sec"}). We observed robust interaction of XRCC1-BRCT1 with a blunt-ended double-stranded DNA (dsDNA) oligonucleotide and a variety of different "damaged" dsDNA molecules with *K*~d~ values in the range ∼0.2--0.4 μM ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}). Oligonucleotides incorporating single-strand gaps bound slightly more tightly than the nicked or intact oligonucleotides, but the presence or absence of 5′-phosphate groups at the nick or gap had little effect on the affinity of the interaction.

Mapping PAR- and DNA-Binding Sites on XRCC1-BRCT1 {#sec2.2}
-------------------------------------------------

We previously showed that mutation of residues in XRCC1-BRCT1 that are topologically equivalent to phosphate-binding residues in other BRCT domains disrupted the interaction of XRCC1 with PAR ([@bib6]). To further characterize the PAR-binding site, we recorded two-dimensional (2D) ^1^H--^15^N heteronuclear single quantum coherence (HSQC) NMR spectra on isotopically labeled samples of human XRCC1-BRCT1 (see [STAR Methods](#sec4){ref-type="sec"}) and measured chemical shift perturbations in the presence of a purified PAR oligomer (PAR4) (see [STAR Methods](#sec4){ref-type="sec"}; [Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}). We observed significant chemical shift perturbations in residues within and proximal to the putative phosphate-binding pocket, including Arg 335 and Lys 369, whose mutation disrupts binding to PAR *in vitro* and XRCC1 recruitment to DNA damage *in vivo* ([@bib6] and see below), confirming our identification of this pocket as critical for PAR binding. The exchange behavior of the chemical shift perturbations observed were in the slow-exchange range, suggesting an affinity for PAR4 in the sub-micromolar range, consistent with previous observations ([@bib23]).Figure 2Mapping PAR- and DNA-Binding Sites(A) ^1^H--^15^N heteronuclear single quantum coherence (HSQC) NMR spectra for XRCC1-BRCT1 alone (black) overlayed with the HSQC spectrum for XRCC1-BRCT1 in the presence of a fragment of poly(ADP-ribose)---PAR4 (cyan; see [STAR Methods](#sec4){ref-type="sec"}). Assignments for these and other spectra have been deposited in the Biological Magnetic Resonance Bank (BRMB: 27598).(B) Close up of boxed region in (A), highlighting residues in and around the putative phosphate-binding pocket in XRCC1-BRCT1, whose chemical shift changes on binding of PAR4.(C) Close up of equivalent region to (B), showing the HSQC spectra for XRCC1-BRCT1 alone (black), overlayed with the HSQC spectrum for XRCC1-BRCT1 in the presence of a 19-mer dsDNA with a 5′-phosphorylated nick on one strand, 8 nucleotides in from the 3′ end (orange)---see [Figure S1](#mmc1){ref-type="supplementary-material"}. Residues whose chemical shifts change on binding of the dsDNA are highlighted.(D) As (C) but showing the overlay of HSQC spectra for XRCC1-BRCT1 bound to PAR4 (cyan) with that of XRCC1-BRCT1 + PAR4 with the addition of nicked, 5′-phosphorylated dsDNA (orange). Residues that display a change in chemical shift on binding of dsDNA to XRCC1-BRCT1 alone display very similar shifts when the dsDNA is added to XRCC1-BRCT1 already bound to PAR4, showing that the binding sites for PAR4 and dsDNA are non-overlapping and that these two ligands are not mutually competitive.(E) Secondary structure cartoon of the NMR structure of XRCC1-BRCT1 (PDB: [2D8M](pdb:2D8M){#intref0060}), with residues showing perturbed peptide backbone chemical shifts on PAR4 binding highlighted in cyan and those whose chemical shifts are perturbed by binding of nicked dsDNA, highlighted in orange. Highlighted residues are those whose chemical shift perturbation exceeds 2 SD of the average chemical shift across the whole domain or those where the peak becomes broadened.(F) As (E) but with a solvent-accessible surface representation showing the non-overlapping binding sites for PAR and for dsDNA on opposite faces of the domain.

^1^H--^15^N HSQC spectra recorded in the presence of a nicked dsDNA oligonucleotide with the internal 5′ end phosphorylated (see [STAR Methods](#sec4){ref-type="sec"}) instead of PAR also display clear chemical shift changes consistent with the sub-micromolar affinity of the nicked DNA for XRCC1-BRCT1 observed in the fluorescence polarization experiments (see above) and confirming an interaction between XRCC1-BRCT1 and DNA. However, most of the observed perturbations upon DNA binding occurred in residues that were not strongly affected by PAR ([Figure 2](#fig2){ref-type="fig"}C), suggesting that the DNA and PAR molecules were binding to distinct sites on XRCC1-BRCT1. We tested this by titrating in increasing amounts of nicked dsDNA into XRCC1-BRCT1 already saturated by PAR4 and observed a pattern of chemical shift perturbations that represented the superposition of perturbations observed for the separate additions of PAR and DNA to protein alone ([Figure 2](#fig2){ref-type="fig"}D).

Mapped onto the NMR solution structure of XRCC1-BRCT1 (PDB: [2D8M](pdb:2D8M){#intref0010}), the sets of residues perturbed by binding of PAR or by binding of DNA define distinct non-overlapping patches on the solvent accessible surface of the domain ([Figures 2](#fig2){ref-type="fig"}E and 2F). The residues perturbed by PAR binding lie on the face of the domain formed by the C-terminal end of the central parallel β sheet and map in and around the phosphate-binding "pocket," which is conserved in many BRCT domains that mediate interaction with phosphorylated peptide motifs ([@bib26]). The residues perturbed by DNA binding localize to the opposite face of the domain within the N-terminal ends of the β strands and from a segment of polypeptide extending from the C-terminal α helix.

Mutation Analysis of the DNA-Binding Site {#sec2.3}
-----------------------------------------

Next, we sought to validate the results of the NMR experiments by exploring the effect of disruptive mutations in the predicted DNA-binding site on biochemical and functional assays. In the absence of a high-resolution structure for a complex, predicting a single point mutation that abrogates XRCC1-BRCT1 interaction with DNA, as we have been able to do with phosphopeptide interactions with other BRCT domains ([@bib41], [@bib42]), is challenging. However, the highly basic nature of the surface patch revealed by NMR titration experiments with DNA suggests that mutations altering the electrostatics should affect interaction of the XRCC1-BRCT1 domain with DNA ([Figure 3](#fig3){ref-type="fig"}A). We therefore mutated a number of residues in this region that were perturbed by DNA binding in the NMR studies and found that an XRCC1-BRCT1-R399D,R400Q double mutant, which would be expected to substantially disrupt the basic nature of the putative DNA-binding site without perturbing the structure of the domain, could be readily expressed and purified as a soluble protein.Figure 3Mutational Analysis of the DNA-Binding Site(A) Solvent-accessible surface of the DNA-binding site colored by electrostatic potential (calculated in PyMol). Residues perturbed by DNA binding (including Arg399 and Arg400) map to an intensely positively charged surface patch (left), whose polarity is predicted to be reversed by the combination of R399D and R400Q mutations (right).(B) PAR-binding assay (see [STAR Methods](#sec4){ref-type="sec"}) of XRCC1-BRCT1 variants and mutants. Both codon 399 variants and the putative DNA binding disruptive R399D,R400Q double mutant bind tightly to PAR chains generated on plates coated with histone H1 and incubated with PARP1 and NAD^+^, whereas no binding is seen with the R335A,K369A double mutant, which affects two residues in the PAR-binding site ([@bib6]). No binding is seen for any of the constructs in the absence of NAD^+^. Data represent the mean of four measurements of three separate replicates analyzed by two-way ANOVA. Error bars show ± 1 SEM.(C) Fluorescence polarization assays of XRCC1-BRCT1 variants and mutants to FITC-labeled nicked dsDNA oligonucleotides with (left) or without (right) 5′ phosphorylation at the nick site. The codon 399 variants and the PAR-binding site mutant all bind with high affinity to both nicked duplex oligonucleotides, whereas the R399D,R400Q double mutant shows very low fluorescence poloarization (FP) values, which cannot be fitted to a binding curve (for *K*~d~ values, see [Figure S1](#mmc1){ref-type="supplementary-material"}B). Data represent the mean of four measurements comprised of two separate replicates with XRCC1-BRCT1 from two separate protein purifications. Error bars show ± 1 SEM.

Human populations have a common CAG → CGG polymorphism in codon 399 (allele frequency between 16%--35%), which results in a glutamine rather than an arginine in the expressed protein ([@bib19]). Multiple studies have suggested association of the G/G and A/G genotypes with enhanced susceptibility to a broad range of cancer types ([@bib11], [@bib15], [@bib34], [@bib35], [@bib38]) and/or variable responses to chemotherapy ([@bib14], [@bib28], [@bib45], [@bib55]). However, other studies and meta-analyses have failed to demonstrate such association, and the significance of this common polymorphism remains controversial ([@bib20], [@bib50], [@bib56], [@bib57]). Because the participation of this polymorphic residue in DNA binding provides the first suggestion of a biochemical role, we compared Gln399 and Arg399 variants of the XRCC1-BRCT1 for functionality, alongside the R399D/R400Q double mutant.

Using a previously described assay ([@bib6]), we tested the ability of the XRCC1-BRCT1 constructs to bind to PAR chains generated on histone H1 by PARP1 in the presence of NAD^+^ (see [STAR Methods](#sec4){ref-type="sec"}; [Figure 3](#fig3){ref-type="fig"}B). PAR binding by the DNA-binding site double mutant and the Gln399 variant were essentially identical to that of the Arg399 XRCC1-BRCT1 domain, whereas a construct with a previously described double mutation in the PAR-binding pocket (R335A, K369A; [@bib6]) failed to interact with PAR. These data demonstrate that the DNA-binding site identified by the NMR titration experiments does not contribute significantly to the interaction with PAR and confirms that neither the double mutation nor the polymorphic variation have any substantial effect on the three-dimensional structure and consequent functional integrity of the BRCT domain.

By contrast, although both codon 399 variants and the PAR-binding pocket mutant protein displayed low or sub-micromolar affinity for 5′-phosphorylated or unphosphorylated nicked dsDNA in a fluorescence polarization assay (see [STAR Methods](#sec4){ref-type="sec"}), the R399D,R400Q double mutant failed to bind DNA, confirming the critical involvement of these residues in DNA binding by XRCC1-BRCT1 ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}).

DNA Binding Is Required for XRCC1-Dependent Repair {#sec2.4}
--------------------------------------------------

To determine whether the ability of XRCC1-BRCT1 to bind DNA plays a role in its function as a DNA repair scaffold, we employed U2OS cells in which the *XRCC1* gene was disrupted by CRISPR/Cas9-mediated gene editing and XRCC1 expression then restored in the edited cells by transfection with wild-type or mutant EGFP-XRCC1 fusion protein (see [STAR Methods](#sec4){ref-type="sec"}).

We observed robust and rapid recruitment of both R399 and Q399 variants of the EGFP-XRCC1 fusion to DNA damage caused by laser micro-irradiation in these cell lines (see [STAR Methods](#sec4){ref-type="sec"}), whereas we failed to detect recruitment of the PAR-binding-defective R335A,K369A double mutant, as previously described ([@bib6]). The R399D,R400Q double mutant that is competent for PAR binding but defective in DNA binding (see above) was still recruited to DNA damage. However, this occurred with markedly slower kinetics than the native variants ([Figure 4](#fig4){ref-type="fig"}A). Chromatin retention of the EGFP-XRCC1 fusion protein following DNA damage was also strongly affected by mutational disruption of the DNA-binding site in BRCT1, with the R399D,R400Q double mutant being as poorly retained as the PAR-binding defective R335A,K369A mutant ([Figure 4](#fig4){ref-type="fig"}B).Figure 4DNA Binding Contributes to XRCC1-Dependent DNA Damage Repair(A) Recruitment of XRCC1 variants and mutants to laser micro-irradiation DNA damage. Both codon 399 variants are rapidly recruited to sites of DNA damage in U2OS cells transiently transfected with GFP-XRCC1 and accumulate to comparable levels over 15--20 s post-laser exposure. Consistent with previous studies ([@bib6]), mutational disruption of XRCC1 PAR binding (R335A,K369A) abolishes XRCC1 recruitment to DNA damage in this time frame. The R399D,R400Q mutant, which is fully competent for PAR binding but defective for DNA binding *in vitro*, still accumulates at sites of damage but with markedly slower kinetics than the DNA-binding and PAR-binding competent constructs. Error bars are SEM for 30 cells analyzed for each curve, except for the R399D,R400Q mutant, where only 10 cells were analyzed.(B) Retention of XRCC1 at DNA damage. Both codon 399 variants showed high levels of retention on chromatin in U2OS cells stably transfected with GFP-XRCC1 10--20 min after exposure to DNA damage by hydrogen peroxide, whereas the PAR-binding defective mutant shows much lower levels. The DNA-binding defective mutant is retained at higher levels than the PAR-binding defective mutant but markedly reduced in comparison to the unmutated variants. Data represent the mean of three measurements, with \>8000 cells per sample per experiment using Perkin-Elmer Operetta software and analysed by two-way ANOVA. Error bars show ± 1 SEM.(C) Untransformed U2OS cells, which carry the R399 XRCC1 variant, display moderate dose-dependent alkaline comet tail moments (see [STAR Methods](#sec4){ref-type="sec"}) after treatment with methyl methanesulfonate (MMS), indicative of unrepaired single-strand breaks (SSBs). U2OS cells where the XRCC1 gene is disrupted by CRISPR/Cas9 gene editing and consequently expresses undetectable levels of XRCC1 protein ([Figure S2](#mmc1){ref-type="supplementary-material"}) show significantly larger tail moments indicative of much higher levels of SSBs. This repair defect can be substantially rescued by expression of GFP-XRCC1 with either codon 399 variant, but not by GFP-XRCC1 with the PAR-binding defect. Consistent with its much reduced DNA binding *in vitro*, its slower recruitment to laser damage, and its poorer chromatin retention post-damage, the R399D,R400Q mutant is significantly less able to rescue SSB repair in the xrcc1^−/−^ cells. Error bars indicate SEM over three replicates ([Figure S3](#mmc1){ref-type="supplementary-material"}). Average tail moments from 100 cells/sample were measured using Comet Assay IV software (Perceptive Instruments, UK) and were scored blind. Data are the average of three independent experiments. Error bars show ± 1 SEM.

Finally, we looked at the ability of the variant and mutant XRCC1 proteins to support DNA repair in U2OS cells following treatment with varying doses of methyl methanesulfonate (MMS), using an alkaline comet assay that reports on unrepaired DNA SSBs ([@bib5]). Wild-type U2OS cells (which contain the R399 *XRCC1* variant) in which the endogenous *XRCC1* gene was disrupted by gene editing accumulated far higher levels of SSBs than did wild-type U2OS cells ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B--S4D). The SSB repair defect in these *XRCC1* gene-edited cells was effectively rescued by expression of either of the residue 399 polymorphic variants of EGFP-XRCC1, but not by the PAR-binding defective R335A,K369A double mutant ([Figure 4](#fig4){ref-type="fig"}C). Expression of the PAR-binding competent but DNA-binding-defective R399D,R400Q mutant resulted in an intermediate level of SSB repair that was significantly reduced compared to wild-type U2OS cells.

Discussion {#sec3}
==========

A direct consequence of the activation of PARP1 and/or PARP2 at DNA strand breaks is the rapid formation of PAR chains covalently anchored primarily to the PARP enzymes themselves ([@bib8], [@bib13]). A primary function of these PAR chains in the context of DNA repair is the recruitment of the XRCC1 scaffold protein to sites of DNA damage ([@bib31], [@bib29], [@bib6], [@bib18]). XRCC1-dependent repair of single-strand DNA breaks generated by oxidative damage, alkylation, or abortive topoisomerase 1 activity requires the catalytic activity of up to four associated DNA repair enzymes (Polβ, Lig3α, PNKP, and APTX), each of which requires access to the 5′ and/or 3′ termini at the margins of the DNA break to perform its particular reaction. To facilitate this, XRCC1 functions as a DNA-binding scaffold protein to help recruit, retain, and coordinate its partner enzymes at the site of damage once PARP1 or PARP2 are released.

The results we present here unambiguously identify the central BRCT domain as both necessary and sufficient for DNA binding by XRCC1 and resolve a long-standing question in the field. The DNA-binding site in the BRCT domain is distinct from the binding site for PAR, which interacts with the conserved pocket that mediates phosphopeptide binding in BRCT domain proteins, such as BRCA1, 53BP1, and TOPBP1 ([@bib2], [@bib12], [@bib22], [@bib27], [@bib41], [@bib44], [@bib48], [@bib54]) and DNA end binding in RFC1 ([@bib24]). Furthermore, the PAR-binding and DNA-binding sites on BRCT1 are non-overlapping, so that both polymers can interact with XRCC1 simultaneously. This would allow a smooth transfer from PAR to DNA as the main anchor for retaining XRCC1 at the site of damage, while its partner enzymes process and repair the DNA break. Consistent with this model, we find that DNA binding, although not essential for recruitment of XRCC1 downstream of PARP activation, contributes to XRCC1 recruitment and retention on damaged chromatin. *In vivo*, this is reflected in a significant reduction in the efficiency of SSB repair. However, like some other XRCC1 mutations that affect SSB repair efficiency ([@bib4], [@bib30]), disruption of DNA binding does not significantly impact cell survival ([Figure S4](#mmc1){ref-type="supplementary-material"}E), probably due to the ability of homologous recombination to compensate for reduced SSB repair during S phase ([@bib8]).

The DNA-binding site we have identified on XRCC1-BRCT1 encompasses residue 399, which has a common Arg/Gln genetic polymorphism in human populations. The significance of this polymorphism is a matter of considerable study and debate, but there is no clear consensus as to whether or not the less common Q399 variant predisposes individuals to a variety of cancers or whether it predicts a better response to a variety of genotoxic chemotherapies---both of which are claimed in the literature. Our data do show small differences in DNA binding and damage recruitment between the Q399 and R399 variants of XRCC1, with the Q399 variant being overall less effective in SSB repair than the R399 variant ([Figure 4](#fig4){ref-type="fig"}C), but none of these differences achieve statistical significance in our hands. Nonetheless, the involvement of this polymorphic residue in a defined biochemical function of XRCC1 may provide a more mechanistic basis for assessing its importance.

Our results reinforce the role of XRCC1 as a spatial organizer of SSB repair, providing a stable protein scaffold on DNA in the vicinity of a break that is completely independent of the highly specific and competing interactions of its partner enzymes with the 3′ and 5′ termini at the margins of the break. How this competition is structurally orchestrated and coordinated by XRCC1 to achieve efficient SSB repair remains to be determined.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**His-affinity tag, mouse monoclonalTakara BioCat\#631212XRCC1 Antibody, rabbit polyclonalBio-techneCat\#NBP1-87154HRP-conjugated mouse anti-mouse IgGGE healthcareCat\#NA931**Bacterial and Virus Strains**NEB 5-alpha Competent *E. coli*New England BiolabsCat\#C2987HBL21(DE3) Competent *E. coli*New England BiolabsCat\#C2527I**Chemicals, Peptides, and Recombinant Proteins**\[^15^N\] NH~4~ClCortecNetCat\#CN80P10\[^13^C3\] glycerolCortecNetCat\#CC1065P10Isopropyl β-D-1-thiogalactopyranosideGeneronCat\#Gen-S-02122HEPESFisher ScientificCat\#10081113NaClFisher ScientificCat\#10735921ImidazoleAcros OrganicsCat\#301870010TCEPSigma-AldrichCat\#646547cOmplete, EDTA-free Protease Inhibitor CocktailSigma-AldrichCat\#4693159001Talon resinTaKaRa BioCat\#635503Calf thymus histonesSigma-AldrichCat\#H9250Tris-HClFisher ScientificCat\#10316893MgCl~2~Fisher ScientificCat\#10386743NAD+Sigma-AldrichCat\#N8410trichloroacetic acidFisher ScientificCat\#10775151EDTAFisher ScientificCat\#10716481KOHFisher ScientificCat\#10448990Ammonium acetateFisher ScientificCat\#10365260Guanidine HClAcros OrganicsCat\#1202300253-Aminophenylboronic acid monohydrateSigma-AldrichCat\#287512Bio-Rex 70 Cation Exchange ResinBio-RadCat\#1425822UreaFisher ScientificCat\#10578260Bromophenol blueFisher ScientificCat\#10679733Xylene cyanolSigma-AldrichCat\#X4126Pierce Color Silver Stain KitFisher ScientificCat\#10096113D~2~OSigma-AldrichCat\#1518826% DNA Retardation GelFisher ScientificCat\#12080086Tris-borate-EDTAFisher ScientificCat\#10542985Gibson AssemblyNew England BiolabsCat\#E2611Lhuman PARP1TrevigenCat\#4668-02K-01Tween 20Sigma-AldrichCat\#P94163,3′,5,5′-tetramethylbenzidineSigma-AldrichCat\#T4319Triton X-100Sigma-AldrichCat\#T9284Dulbecco's Phosphate-Buffered Saline (PBS)ThermoFisher ScientificCat\#14190136Hoechst 34580Sigma-AldrichCat\#63493Dulbecco's modified Eagle's medium (DMEM)ThermoFisher ScientificCat\#21969035Foetal bovine serumSigma-AldrichCat\#F7524GlutamineThermoFisher ScientificCat\#25030081Penicillin-StreptomycinSigma-AldrichCat\#P4333GenejuiceNovagenCat\#70967BlasticidinInvivoGenCat\#ant-bl-1Methyl methanesulfonateSigma-AldrichCat\#129925Low-gelling-temperature agarose, Type VII-ASigma-AldrichCat\#A0701DMSOSigma-AldrichCat\#276855SybrGreen IFisher ScientificCat\#S7563Hydrogen peroxideSigma-AldrichCat\#H1009ParaformaldehydeAgar ScientificCat\#AGR1026Hoechst 33342Sigma-AldrichCat\#B2261ECL reagentFisher ScientificCat\#10455145PD MidiTrap G-10 columnSigma-AldrichCat\#GE28-9180Tankyrase 1([@bib17])N/A**Deposited Data**Biological Magnetic Resonance Bank27598**Experimental Models: Cell Lines**Osteosarcoma U2-OSGenome Damage and Stability Centre cell repositoryID: U2-OS**Oligonucleotides**Oligonucleotides for DNA-binding experiments, see [Figure S1](#mmc1){ref-type="supplementary-material"}.Integrated DNA TechnologiesN/A**Recombinant DNA**pET15bNovagen69661peGFP-N1Clontech6085-1pET15b-SUMO-XRCC1-BRCT1This paperN/A**Software and Algorithms**GraphPad Prism7 for Mac OS XGraphpad<https://www.graphpad.com/scientific-software/prism/>SlideBook 63i<https://www.intelligent-imaging.com/slidebook>CcpNmr AnalysisCollaborative Computing Project for NMR<https://www.ccpn.ac.uk/>Comet Assay IV softwarePerceptive Instruments<http://www.scorecomets.com/comet-scoring/comet-assay-iv>Harmony high-content analysis softwarePerkinElmerCat\#HH17000001ImageJ64ImageJ Software<https://imagej.nih.gov/ij/>**Other**BD FACSMelodyBD BiosciencesN/AOperetta CLS high-content analysis systemPerkinElmerCat\#HH160000003i Spinning Disk Confocal microscope3iN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Prof. Laurence Pearl FRS (<Laurence.Pearl@sussex.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell culture {#sec4.3.1}

The osteosarcoma cell line U2-OS (obtained from the Genome Damage and Stability Centre cell repository) was maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% (vol/vol) fetal bovine serum, 100 U/ml penicillin, 2 mM glutamine and 100 μg/ml streptomycin.

Method Details {#sec4.4}
--------------

### Cloning {#sec4.4.1}

DNA encoding the required region of human XRCC1 was amplified by PCR from human cDNA. DNA encoding human 6xHis-SUMO-XRCC1-BRCT1^301-410^ was amplified by PCR, using synthetic DNA codon-optimized for expression in *E. coli* as a template (Genscript, Piscataway, USA). Primers were designed to sub-clone the amplified DNA into vectors suitable for protein expression in *E. coli* by Gibson Assembly (New England Biolabs).

### Expression and purification {#sec4.4.2}

*E. coli* strain BL21(DE3) (Merck Millipore) was co-transformed with pET15b-SUMO-XRCC1-BRCT1 plasmid. Transformants were selected on LB-agar plates added with antibiotics. From an overnight culture, 25 ml was used to inoculate a 2 l flask, containing 1 l of Turbo-broth media (Molecular Dimensions, Newmarket, UK) again supplemented with antibiotics. Cultures were grown in an orbital-shaking incubator, at 37°C, until an optical density of ∼1.5 units at a wavelength of 600 nm was reached. The temperature was then reduced to 20°C, and recombinant protein expression induced by the addition of 0.15 M isopropyl β-D-1-thiogalactopyranoside. Cells were subsequently harvested by centrifugation after 16 h at the reduced temperature. The resultant pellet was stored at −20°C until required.

For NMR experiments, the protein was expressed in 1 l filter-sterilized Overnight Express Autoinduction NMR Media (Merck-Millipore, Billerica, MA, USA) containing 50 mM \[^15^N\] NH4Cl and 0.5% (w/v) \[^13^C3\] glycerol (CortecNet, Voisins-le-Bretonneux, France) at a temperature of 25°C for 30 h.

The cell pellet resulting from 4 l of culture was resuspended in Buffer A (50 mM HEPES.NaOH pH 7.5, 250 mM NaCl, 10 mM imidazole, 0.5 mM TCEP) supplemented with protease inhibitor tablets (Roche, Burgess Hill, UK). Cells were then disrupted by sonication, and insoluble material removed by centrifugation. The resultant supernatant was incubated with Talon resin (TaKaRa Bio) pre-equilibrated in Buffer A. After successive washes with Buffer A to remove unbound material, the retained recombinant proteins were eluted by the additon of Buffer B (50 mM HEPES.NaOH pH 7.5, 250 mM NaCl, 300 mM imidazole, 0.5 mM TCEP). The affinity tag and SUMO were then cleaved by overnight incubation with SENP1 at 4°C. The proteins were concentrated to a final volume of 3 ml using Vivaspin 20 (10,000 MWCO) centrifugal concentrators (Sartorius Stedim Biotech, Goettingen, Germany) and then loaded onto a Superdex 75 size exclusion chromatography column (GE Healthcare Life Sciences, Little Chalfont, UK) pre-equilibrated with Buffer C (20 mM HEPES.NaOH pH 7.5, 250 mM NaCl, 0.5 mM TCEP) as the final purification step. Fractions containing the purified complex were identified by SDS-PAGE, pooled and then concentrated to 11 mg ml^−1^ and either used immediately or flash-frozen in liquid N~2~ and stored at −80°C until required.

### Poly(ADP-ribose) preparation {#sec4.4.3}

The purification protocol is based on ([@bib49]) with some minor alterations. The PARylation reaction was as follows: 1mg/ml calf thymus histones (Sigma-Aldrich) in PARP reaction buffer (50mM Tris-HCl pH 8, 0.8mM MgCl2, 1% v/v glycerol and 0.5mM DTT), 200mM NAD+ (Sigma-Aldrich) were mixed with 1mg/ml tankrase 1 enzyme. The reaction was stopped after 1 hour at room temperature by adding an equal volume of 20% v/v ice-cold trichloroacetic acid, and incubated on ice for 15 min. The precipitated ribosylated protein was pelleted by centrifugation at top speed at 4°C, dissolved in 100μl 1M KOH/50mM EDTA and was incubated for 60 min at 60°C. Then, AAGE9 buffer (250mM ammonium acetate, 6M guanidine HCl, 10mM EDTA, pH 9.0) was added and the sample was loaded onto 1ml dihydroxyboryl Bio-Rex resin pre-equilibrated with AAGE9 buffer. The dihydroxyboryl resin was prepared by coupling BioRex 70 beads, (100-200 mesh, Bio-Rad) and N-ethyl-N'-(3-diethylaminopropyl)-carbodiimide (Sigma-Aldrich), as described ([@bib53]). The resin was washed with 10 column volumes (cv) AAGE9 buffer, 20cv 1M ammonium acetate pH 9.0 buffer, eluted with 6cv water and collected in 1cv fractions. Successive fractions were analyzed by UV spectroscopy (258nm), using a NanoDrop2000 (Thermo Fisher Scientific) and fractions containing bulk PAR were loaded onto a 1ml MonoQ 5/50 chromatography column (GE Healthcare). The column was extensively washed with Buffer A (25mM Tris-HCl, pH9.0) to remove any unbound material. Bound PAR was eluted by the application of the following linear gradient series from Buffer A to Buffer B (25mM Tris-HCl, pH 9.0, 1M NaCl): 0% to 15% B over 5cv, then 15% to 40% B over 130 cv, followed by 40% to 45% B over 80cv, and a final step from 45% to 100% B over 3cv. Fractions were dried in a Savant DNA120 SpeedVacTM concentrator (Thermo Fisher Scientific) and stored at −20°C until required. Fractions containing PAR with the same elution volume, were loaded together onto a PD MidiTrap G-10 column (GE Healthcare) pre-equilibrated with water, eluted following the manufacturer's protocol and again dried before being stored at −20°C. Purified PAR fractions were adjusted to a final concentration of 0.3μM and then diluted in loading buffer (40% w/v urea, 4mM EDTA, 0.02% w/v Bromophenol blue, and 0.02% w/v Xylene cyanol) to a final volume of 15μl and then loaded onto a 20% v/v polyacrylamide gel (Thermo Fisher Scientific) containing 1x TBE buffer. The gel was run at a constant power of 15W until the dye front migrated approximately 50% of the gel; after which the gel was fixed in a 50% v/v ethanol and 5% v/v acetic acid solution for 2 hours, and washed with ultrapure water. It was stained with a Pierce Color Silver Stain Kit (Thermo Fisher Scientific) following manufacturer's protocol.

### NMR resonance assignment {#sec4.4.4}

NMR spectra were recorded at 303K on Bruker DRX600 and DRX800 spectrometers equipped with cryo-probes. XRCC1-BRCT1 was dissolved in 300 μl NMR buffer containing 20 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1 mM TCEP and 10% D~2~O to a final concentration of ∼350 μM. The chemical shifts of ^1^HN, ^15^N, ^13^Cα, ^13^Cβ and ^13^CO cross-peaks were assigned using CBCA(CO)NH, HNCACB, HNCO and HN(CA)CO experiments and data were analyzed using the program CCPNMR Analysis ([@bib46]). \> 90% of the amino acid backbone resonances were assigned. A similar procedure was followed to assign chemical shifts after formation of complexes between XRCC1-BRCT1 and DNA (oligonucleotides detailed in [Figure S1](#mmc1){ref-type="supplementary-material"}) or Poly (ADP-ribose). For binding of DNA to the BRCT1-PAR complex, the BRCT1 was saturated by addition of PAR4 until no further chemical shift was obtained. After saturation with PAR4 and DNA, peaks were reassigned in the HSQC spectrum using HNCA data. Chemical shift perturbations (CSP) were calculated as: \[^1^HΔ^2^ + (0.15^∗15^NΔ) ^2^\]^0.5^. NMR data has been deposited in the Biological Magnetic Resonance Bank with accession number [27598](ncbi-mmdb:27598){#intref0045}.

### Electrophoretic Mobility Shift Assay {#sec4.4.5}

Oligonucleotides at a concentration of 100 nM, were mixed with increasing concentrations of constructs of XRCC1, in 20 mM HEPES.NaOH pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM TCEP, and incubated for 10 min at room temperature. Samples were then analyzed on 6% v/v native polyacrylamide gels (6% DNA Retardation Gel, ThermoFisher Scientific) containing 0.5X tris-borate-EDTA (TBE) and visualized by direct scanning of the gel in a Fuji FLA-5100 Fluorescent Image Analyzer.

### Fluorescence polarization {#sec4.4.6}

Fluorescent dsDNA oligonucleotides were assembled as shown in [Figure S1](#mmc1){ref-type="supplementary-material"}, with fluorescein isothiocyanate attached to the 5′-terminus of the continuous strand. For fluorescent polarization experiments, annealed oligonucleotides at a concentration of 10 μM were incubated with increasing concentrations of wild-type XRCC1-BRCT1, in 20 mM HEPES.NaOH pH7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM TCEP, and incubated for 10 min at room temperature. Fluorescence polarization was measured in a POLARstar OMEGA multimode plate reader (BMG Labtech GmbH, Offenburg, Germany).

### Poly (ADP-ribose) binding assays {#sec4.4.7}

The wells of flat bottomed 96 well PS-microplates (Greiner) were incubated with either 50 μL recombinant histone H1 at 0.1 mg/ml in phosphate buffered saline (PBS) overnight at 4°C and the wells rinsed (4 × ) with 0.2 mL 0.1% Triton X-100 in PBS. The adsorbed proteins were mock ribosylated in the absence of NAD+ or ribosylated in the presence of the 50 mM NAD+ (Sigma) in PARP1 reaction buffer (50 mM Tris--HCl pH7.5, 0.8 mM MgCl~2~, 1% glycerol and 1.5 mM DTT) containing 40 nM single-stranded oligodeoxyribonucleotide (5′-CATATGCCGGAGATCCGCCTCC-3′) and 5 nM human PARP1 (Trevigen) in a final volume of 50 μL at room temp for 30 min. After rinsing (4 × ) with 50 μL of 0.1% Tween 20 in PBS, 50 μL of His-SUMO-XRCC-BRCT1 or its variants (diluted to 25 nM in 20 mM Tris pH7.5, 130 nM NaCl) were added to the adsorbed proteins and incubated on ice for 30 min. The wells were then rinsed (4 × ) as above and incubated with 50 μL mouse anti-polyhistidine (His-tag) Mab (Takara Bio, diluted 1:2500 in 20 mM Tris pH7.5, 130 nM NaCl) followed by 50 μL HRP-conjugated mouse anti-mouse IgG (ECL, GE Healthcare, 1: 5000 in dilution buffer) for 30 min each on ice. After a final wash with 3,3′,5,5′-tetramethylbenzidine liquid substrate, slow kinetic form (Sigma-Aldrich) was added to the wells, incubated in the dark for 10 min, stopped by adding 0.2 M HCl, and the absorbance was read at 450 nm.

### UVA-laser micro-irradiation {#sec4.4.8}

ORFs encoding human XRCC1-R399-GFP was generated by PCR amplification of the human XRCC1 ORF and subcloning using Gibson Assembly (New England Biolabs) in peGFP-N1. Point mutations in the BRCT1 domain were generated by site-directed mutagenesis. Osteosarcoma U2-OS cells were seeded onto glass-bottom dishes (Nunc, Thermo Scientific) and transfected with 1 μg of the indicated GFP constructs 24 h before micro-irradiation and incubated with 10 μg ml^−1^ Hoechst 34580 for 30 min before irradiation. Cells were micro-irradiated with a 405 nm UV-laser at a dose of 0.22 μJ μm^−2^ ([@bib6]), and time-lapse images recorded at 0.5 s intervals for a total of 3 min per cell using a Spinning Disk Confocal microscope (3i).

### Generation of gene-edited U2-OS cells {#sec4.4.9}

*XRCC1 gene edited* U2OS cells, denoted in the figures as *XRCC1*^*−/−*^ for simplicity, were generated using the Cas9 and XRCC1 guide expression constructs as previously described ([@bib18]). This cell line will be described in detail, elsewhere. Successful gene editing was confirmed by Sanger sequencing and by western blotting ([Figure S2](#mmc1){ref-type="supplementary-material"}).

### Cell lines expressing XRCC1 {#sec4.4.10}

The cell lines with U2OS-GFP-XRCC1 WT and its variants were generated by transfection of 1 × 10^6^ *XRCC1*^*−/−*^ U2OS cells with 0.5 μg of vectors by Genejuice transfection (Novagen). Twenty four hours after transfection, cells were selected in media containing 7.5 μg ml^-1^ of Blasticidin (InvivoGen) for 3 weeks, and a population of cells were selected based on their level of GFP expression by using a Melody cell sorter (BD).

### Alkaline comet assays {#sec4.4.11}

Osteosarcoma U2-OS cells were treated with 0.1 and 0.2 mg/ml of MMS at 37°C. Cells were then suspended in pre-chilled Dulbecco's PBS and mixed with an equal volume of 1.2% low-gelling-temperature agarose (Sigma, type VII) maintained at 42°C. Cell suspension was immediately layered onto pre-chilled frosted glass slides (Fisher) pre-coated with 0.6% agarose and maintained in the dark at 4°C until set, and for all further steps. Slides were immersed in pre-chilled lysis buffer (2.5 M NaCl, 10 mM Tris-HCl, 100 mM EDTA, 1% Triton X-100, 1% DMSO; pH10) for 1 h, washed with pre-chilled distilled water (2 × 5 min), and placed for 45 min in pre-chilled alkaline electrophoresis buffer (50 mM NaOH, 1 mM EDTA, 1% DMSO). Electrophoresis was then conducted at 1 V/cm for 25 min, followed by neutralization in 400 mM Tris-HCl pH7.4 overnight. Finally, DNA was stained with SybrGreen I (1:10,000 in PBS) for 30 min. Average tail moments from 100 cells/sample were measured using Comet Assay IV software (Perceptive Instruments, UK). Data are the average ± 1 SEM of three independent experiments and were scored blind.

### Chromatin associated XRCC1 {#sec4.4.12}

XRCC1^−/−^-U2OS stably expressing GFP-XRCC1 WT and variants were mock-treated or treated with 1 mM hydrogen peroxide (H~2~O~2~) for 10 min, incubated at 37°C in drug free media for indicated times, pre-extracted with 0.2% Triton X-100 for 2 min, washed with phosphate buffered saline (PBS), then fixed for 10 min in 4% paraformaldehyde in PBS at room temperature and stained with Hoechst 33342 (blue, Sigma-Aldrich, B2261).

### Cell survival assay {#sec4.4.13}

Clonogenic survival was determined by colony formation assays. Briefly, U2-OS cells were counted and plated in DMEM medium containing 10% FBS. Cells were treated with MMS and after incubation for 10 days colonies that were visible by eye were counted. Survival was calculated by dividing the number of colonies in treated wells by those in untreated wells.

### SDS-PAGE and western blotting {#sec4.4.14}

Cells were collected and lysed in SDS sample buffer (2% SDS, 10% glycerol, 50 mM Tric-Cl, pH 6.8), denatured for 10 min at 95°C, and sonicated for 30 s using Bioruptor® Pico (Diagenode). Samples were subjected to SDS-PAGE, proteins transferred onto nitrocellulose membrane and detected by relevant specific antibodies combined with horseradish peroxidase-conjugated secondary antibodies. Peroxidase activity was detected by ECL reagent (GE Healthcare) in an ImageQuant LAS-4000 image reader (GE life sciences). Primary antibodies: His-affinity tag, mouse monoclonal at 1:5000 dilution (631212, Takara Bio) and XRCC1 Antibody, rabbit polyclonal at 1:2000 (NBP1-87154, Bio-techne). Band intensities were determined using ImageJ64 (ImageJ Software).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analyses were performed using GraphPad Prism. Binding data from fluorescent polarization were analyzed with GraphPad Prism 7.0, by non-linear fitting with a one-site binding model, to give the reported dissociation constants (Kd). All data from fluorescent polarization experiments represent the mean of four measurements comprised of two separate replicates with XRCC1-BRCT1 from two separate protein purifications. Data from Poly (ADP-ribose) binding assays was the result of represent the mean of four measurements of three separate replicates and it was analyzed by two-way ANOVA. Average comet tail moments from 100 cells/sample were measured using Comet Assay IV software (Perceptive Instruments, UK). Quantification of detergent-insoluble XRCC1 signal from \> 8000 cells per sample per experiment using Perkin-Elmer Operetta analysis software and analyzed by two-way ANOVA. Comet assay data and cell survival results were scored blind and are shown as the average ± 1 SEM of three independent experiments, compared using two-way ANOVA. Western blot band intensities were analyzed by one-way ANOVA.

Chemical shift perturbations (CSP) were calculated as: \[^1^HΔ^2^ + (0.15^∗15^NΔ)^2^\]^0.5^.

Data and Software Availability {#sec4.6}
------------------------------

NMR assignment data have been deposited into the Biological Magnetic Resonance Data Bank with accession number [27598](ncbi-mmdb:27598){#intref0050}. No other large datasets are associated with this work. All other data are available from the authors on request.
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